Response to baricitinib therapy in patients with rheumatoid arthritis with inadequate response to csDMARDs as a function of baseline characteristics-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Response to baricitinib therapy in patients with rheumatoid arthritis with inadequate response to csDMARDs as a function of baseline characteristics

Published:2018-01 Issue:1 Volume:4 Page:e000581
ISSN:2056-5933
Container-title:RMD Open
language:en
Short-container-title:RMD Open

Author:

Kremer Joel M,Schiff Michael,Muram David,Zhong Jinglin,Alam Jahangir,Genovese Mark C

Funder

Incyte Corporation

Eli Lilly and Company

Publisher

BMJ

Subject

Immunology,Immunology and Allergy,Rheumatology

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of Janus kinase inhibitors in rheumatoid arthritis;Inflammation Research;2023-04-22

2. Toward Overcoming Treatment Failure in Rheumatoid Arthritis;Frontiers in Immunology;2021-12-23

3. Authors’ Response to Letter to the Editor Regarding Comparative Efficacy of JAK Inhibitors for Moderate-to-Severe Rheumatoid Arthritis: A Network Meta-Analysis;Advances in Therapy;2021-03-20

4. Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis—a comprehensive review;Arthritis Research & Therapy;2021-01-04

5. Baricitinib in the treatment of rheumatoid arthritis: clinical and ultrasound evaluation of a real-life single-centre experience;Therapeutic Advances in Musculoskeletal Disease;2021-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP